Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04259346 · ClinicalTrials.gov registry record · Phase 1
A Study of Two Formulations of Ixekizumab in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 245
- Enrollment target
NCT04259346 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 245 participants.
The verdict
NCT04259346, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 245 participants
- Enrollment target
Study Summary
The purpose of this study is to compare two different formulations of ixekizumab. One formulation (Reference) is approved by the Food and Drug Administration (FDA) and one formulation (Test) is not approved. This study will compare how much of each formulation gets into the blood stream. Information about any side effects that may occur will also be collected. The study will last up to about four months for each participant.
Interventions
- DRUG Ixekizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 245 participants |
| Start Date | 2020-02-05 |
| Est. Completion | 2021-02-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04259346
The ClinicalTrials.gov registry entry for NCT04259346 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 245 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ixekizumab is the first listed.
NCT04259346 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04259346 about?
NCT04259346 is a clinical study titled "A Study of Two Formulations of Ixekizumab in Healthy Participants". The purpose of this study is to compare two different formulations of ixekizumab. One formulation (Reference) is approved by the Food and Drug Administration (FDA) and one formulation (Test) is not approved. This study will compare how much of each formulation gets into the blood stream. Information...
What is the current status of trial NCT04259346?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 245 participants. The study started on 2020-02-05. Estimated completion is 2021-02-19.
What interventions are being tested in trial NCT04259346?
The interventions under investigation include: Ixekizumab (DRUG).
Who is sponsoring clinical trial NCT04259346?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.